YouTube · Q2 2026 · 2026-08-13
RMD · NYSE
ResMed
Medical Instruments & Supplies · United States
USD 223.650.4% daily changeQuote 2026-10-06 · USD
- Market cap (USD)
- US$31.45B
- Trailing P/E
- 21.44x
- Forward P/E
- 16.90x
- Quarterly revenue growth
- 8.6%
- Trailing net margin
- 26.9%
- Indicated dividend yield
- 1.2%
Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-29 (provider estimate, not issuer-confirmed).
Company background
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Company websiteQ4 FY2026
Go beyond the headline.
ResMed (RMD): The Miss That Never Happened - And The One Number That Worries Us
Published 2026-08-07
Comparable businesses
RMD peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | RMDResMed Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | ALCAlcon Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | WSTWest Pharmaceutical Services, Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$31.45B | US$30.66B | US$26.43B | US$28.54Bn=2 |
| Forward P/EProvider forward earnings estimate | 16.90x | 15.98x | 37.63x | 26.81xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 15.03x | 14.53x | 28.94x | 21.73xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 8.6% | 8.7% | 13.8% | 11.2%n=2 |
| Operating marginLatest reported quarter | 30.9% | 14.6% | 22.5% | 18.5%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 3.0% | 4.2% | 1.1% | 2.6%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | -0.31x | 1.60x | -0.13x | 0.73xn=2 |
| Debt / equityTotal debt / positive book equity | 0.13x | 0.25x | 0.11x | 0.18xn=2 |
| Trailing P/ETrailing twelve-month earnings | 21.44x | 48.05x | 48.08x | 48.06xn=2 |
| Price / bookPrice / positive book equity per share | 4.90x | 1.42x | 8.84x | 5.13xn=2 |
| EV / salesEnterprise value / trailing revenue | 5.57x | 3.22x | 7.93x | 5.58xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | 2.4% | — | 18.1% | — |
| Gross marginTrailing twelve months | 61.6% | 57.2% | 36.8% | 47.0%n=2 |
| Net marginTrailing twelve months | 26.9% | 5.9% | 17.0% | 11.4%n=2 |
| Return on equityProvider trailing return; positive equity only | 24.3% | 2.9% | 19.1% | 11.0%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 16.6% | 11.7% | 8.4% | 10.0%n=2 |
| Dividend yieldIndicated annual dividend / price | 1.2% | 0.6% | 0.2% | 0.4%n=2 |
| Earnings payoutProvider trailing dividend payout | 23.0% | 26.6% | 11.1% | 18.9%n=2 |
| Current ratioCurrent assets / current liabilities | 3.10x | 2.09x | 2.82x | 2.46xn=2 |
| BetaProvider historical market sensitivity | 0.75 | 0.73 | 1.12 | 0.93n=2 |
YouTube · Q2 2026 · 2026-08-13
West Pharmaceutical Services, Inc. (WST)
Similar size · 0.84x market cap
Medical Instruments & Supplies
YouTube · Q2 2026 · 2026-07-23
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for RMD
Q4 FY20262026-08-07
ResMed (RMD): The Miss That Never Happened - And The One Number That Worries Us
Presentation · 2026-08-07 · YouTube
Q1 20262026-05-04
RMD Stock: Revenue Beats, EPS Misses — Q1 2026
Presentation · 2026-05-04 · YouTube